John Newman

Regeneron Requests Emergency Use Authorization, Analysts See Coronavirus Antibodies As Earnings Driver In 2021

Bluebird Bio's Multiple Myeloma Data Reinforces Canaccord Genuity's Bullish Thesis

Canaccord Slices Regeneron Price Target 32% On Eylea, Dupixent Challenges

Bluebird Bio's Multiple Myeloma Data Reinforces Canaccord Genuity's Bullish Thesis

Canaccord Slices Regeneron Price Target 32% On Eylea, Dupixent Challenges

What's Next For Regeneron After A Therapy Trial Failure?

Don't Judge A Note By Its Title: Aurinia Falls On Misinterpreted 'Downgrade'

What's Next For Regeneron After A Therapy Trial Failure?

Don't Judge A Note By Its Title: Aurinia Falls On Misinterpreted 'Downgrade'

Amgen News Has Major Readthrough For Radius Health

Takeda's Speculative Interest In Synergy Soothes Stomach Pains; Canaccord Says Buy

John Newman Recent News

Safety Remains A Top Concern For Kite Pharma After Positive Phase 1 ZUMA-1 Data

Gemphire Therapeutics' Oral Cholesterol Drug Could Have $2.8 Billion Potential In U.S. Market

Canaccord Sees $40 In Upside For Agios, Upgrades To Buy

Is Medivation's Congressional Letter Just Noise?

Kite Pharma Shares Its Vision: Here's How Wall Street Is Reacting

Canaccord Downgrading Agios To Hold

Canaccord Hot And Cold On Deals By Teva Pharmaceutical, ImmunoGen

UPDATE: Canaccord Genuity Initiates Coverage on Regeneron Pharmaceuticals on Expected Continued Pipeline Success

UPDATE: Canaccord Genuity Assumes Coverage on NPS Pharmaceuticals on Recent Market Weakness

UPDATE: Canaccord Genuity Initiates Coverage on Medivation as Urologist Uptake is Unclear

UPDATE: Canaccord Genuity Initiates Coverage on Lpath on iSONEP Potential

UPDATE: Canaccord Genuity Initiates Coverage on ImmunoGen Ahead of Phase 3 Data

Warner Chilcott Receives 2nd PIV Challenge for Asacol (WCRX)

Oppenheimer Upbeat About Questcor Pharmaceuticals (QCOR)

Oppenheimer Rates Eurand N.V. (EURX) Outperform

Oppenheimer Maintains Salix Pharmaceuticals (SLXP) Outperform Rating